Background {#Sec1}
==========

Duchenne Muscular Dystrophy (DMD) is a rare neuromuscular X-linked disorder that belongs to a group of disorders known as dystrophinopathies. DMD is caused by mutations in the dystrophin gene that lead to the absence of dystrophin or structural defects of this protein. The lack of functional dystrophin in turn impairs the structure and function of myofibres which are essential for physiological growth of muscle tissue \[[@CR1]\]. Due to the localization of the dystrophin gene on the X chromosome, DMD predominantly affects male children, while females are likely to be asymptomatic "healthy carriers" \[[@CR2]\].

DMD is characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest early, at around 3 years, causing loss of ambulation within the 13 year of life, followed by cardiac complications (e.g. dilated cardiomyopathy and arrhythmia) and respiratory disorders, including chronic respiratory failure \[[@CR3]\]. In the first phase of the disease, the child experiences difficulty in running, climbing stairs, jumping, getting up from the ground, falls frequently and develops a wadding gait with a positive "Gowers' sign" \[[@CR1]\]. The subsequent impairment of the cardiac and respiratory systems is the main cause of death for these patients. Survival is linked to cardiac involvement and has greatly improved thanks to the use of nocturnal ventilation and spinal surgery, with 30% patients surviving beyond 30 years of age \[[@CR4]\] and a median survival improved to 30 years \[[@CR5]\]. A proportion of DMD patients also experience behavioral and cognitive impairment with intellectual disability, attention hyperactivity disorder (ADHD) and autism spectrum disorders \[[@CR6]\]. The disease burden and economic costs are very high and dramatically increase with disease progression \[[@CR7]\]. The different burden of comorbidity and mortality in DMD and resulting healthcare utilization patterns compared to the general population highlight the importance of studying DMD populations in detail. The epidemiology of DMD is expected to be generally similar globally, because there is no specific population with a known higher risk. However, variations may arise because of differences in study design and quality. As a result, pooled epidemiological estimates may be considered much more robust and reliable than estimates from single studies. Generating such epidemiological evidence on rare diseases like DMD is fundamental to evaluate the population impact of the disease in terms of burden of disease, to identify unmet clinical needs and to identify eligible target populations for drugs prior to their being marketed. The latter role of epidemiologic research is highlighted in the case of DMD since there are currently only two drugs specifically licensed for the treatment of DMD patients. Specifically, ataluren is licensed in Europe for the treatment of DMD patients with nonsense mutations, (approximately 10--15% of DMD cases) \[[@CR8]\], while eteplirsen is licensed in the United States for the treatment of DMD patients who have a confirmed mutation that is amenable to exon 51 skipping (approximately 13% of DMD cases) \[[@CR9]\]. This has an important impact on regulatory decisions including the decision to market a drug or not and important cost considerations such as whether a healthcare system is willing to pay for the drug or the adoption of managed entry agreements \[[@CR10]\].

In the last 5 years, one narrative and two systematic literature reviews have summarized the global epidemiological evidence on muscular dystrophies \[[@CR7], [@CR11], [@CR12]\]. In a recent review, evidence gaps have been highlighted particularly in prevalence and mortality \[[@CR7]\] and the economic impact of this disease on healthcare systems is very high due to the needed multidisciplinary care and increases with disease progression, it is crucial to gather updated information on its prevalence, in order to ensure that resources and appropriate services are available for DMD patients world-wide. Moreover, the reviews only included studies up to 2015. This highlights the need to fill the four-year gap to provide updated information. Moreover, previous DMD epidemiology systematic reviews have pooled epidemiological data on DMD, but none of them have in addition performed the quality assessment of the included studies. In general, it is difficult to interpret the results of a study without evaluating its quality and this holds true specifically in rare diseases. The lack of an updated systematic review and meta-analysis which also evaluates study quality in order to aid the interpretation of the meta-analysis itself emerged clearly \[[@CR11]\]. The aim of this study is therefore to update the previous systematic review and meta-analysis and to provide a quality assessment of the available epidemiological studies.

Methods {#Sec2}
=======

Literature search strategy and selection criteria {#Sec3}
-------------------------------------------------

This systematic review and meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR13]\], the completed checklist can be found in the Additional file [1](#MOESM1){ref-type="media"}. The bibliographic databases MEDLINE and EMBASE were searched individually by two authors (SC, JS) for literature on the epidemiology of DMD from inception until the 1st October 2019. Both databases were searched for terms related to DMD, incidence, prevalence and epidemiology. Citations, titles and abstracts were exported into Endnote X9. The detailed literature search strategy for different databases is provided in Additional file [2](#MOESM2){ref-type="media"}.

Only original observational research articles which reported a numerical and well-defined measure of DMD occurrence, such as prevalence, birth prevalence and/or incidence of DMD and were written in English were included. No geographic exclusion criteria were imposed. Narrative or systematic reviews, meta-analyses, book chapters, editorials, personal opinions and conference abstracts were not included; however, the reference lists in reviews and meta-analyses were screened to potentially identify further studies to include. Studies were also excluded if they did not report the year in which the measure of occurrence was estimated. Information on the following items was collected: data source, study population, study years, study design, DMD outcomes description and measure of occurrence. Studies based on segregation analyses were not considered eligible for inclusion. Segregation analyses are methods that use statistical models to propose different hypotheses on the manner of biological inheritance, especially as a function on environmental factors. The epidemiological measures of frequency identified by these studies are therefore generally *predicted*, rather than actual, incidence or prevalence \[[@CR14]\]. Only studies reporting the number of DMD cases as well as the underlying population were included in this analysis. If a study presented more than one estimate, the most recent one was used.

After removing duplicates from the two different databases, two review authors (SC, JS) individually screened the titles and abstracts of all records identified to remove articles that were clearly irrelevant; full text articles were then examined to determine whether they met the criteria for inclusion in the review. Any divergences were resolved through discussion or the intervention of a third review author (GT).

Data extraction and quality of study reporting assessment {#Sec4}
---------------------------------------------------------

Data were individually extracted from the included articles by two authors (SC and JS). The collected information included author(s), year of publication, study catchment area (i.e. geographic zone), data source (i.e. administrative databases, hospital and clinics medical reviews, surveys and other registries), study population (i.e. all living individual, patients and newborns), study period (i.e. the calendar years at which prevalence was measured), study design (i.e. cross-sectional, survey, prospective and retrospective cohorts or chart-review), DMD definition (i.e. ascertained by clinical examination, muscle biopsy and genetic screening) and the epidemiological estimate, i.e. the main outcome. All measures of DMD epidemiology identified in the articles were classified as either (overall) prevalence and birth prevalence. Prevalence was defined as the number of DMD cases identified at any time, including newly and non-newly diagnosed cases, in a source population potentially at risk prior to birth (i.e. all living persons in a well-defined catchment area), irrespective of age. Birth prevalence was defined as the number of DMD cases identified at birth, including only newly-diagnosed cases, in a source population potentially at risk prior to birth (i.e. all live births in the catchment area) \[[@CR15]\]. Prevalence was calculated as the number of DMD cases divided by the individuals underlying the source population (and was multiplied by 100,000) and was distinguished between "point prevalence", if estimated at a specific calendar year (i.e. the last study period year), and as "period prevalence" if estimated during the whole study period. Studies purporting to measure incidence were considered to constitute birth prevalence because this term is more fitting in the case of congenital anomalies, since the occurrence of congenital defects is often evaluated as a cumulative risk (e.g. number of events per 1000 persons), not as a rate of event occurrence per person-time among healthy individuals \[[@CR16]\]. Such studies could include genetic screening at birth or other similar evaluations carried out on newborns and are likely to have higher epidemiological estimates compared to evaluations carried out later in life, as some patients may not have survived adulthood. These studies were therefore considered separately. The quality of study reporting was independently assessed by two reviewers (SC, JS) using a checklist adapted from STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) specifically for observational studies concerning rare diseases epidemiology \[[@CR17]\].

Study quality was as classified as low, medium or high concerning the following five fields: description of study design and setting, description of eligibility criteria, study population, description of outcomes and description of the study participants. An overall score of low, medium and high was then assigned to each study. The full algorithm used to assign study quality is found in Additional file [3](#MOESM3){ref-type="media"}. Disagreements in score assignments were resolved through discussion or the intervention of a third review author (GT).

Statistical analysis {#Sec5}
--------------------

For each included study, the overall and birth prevalence of DMD per 100,000 individuals was considered as the primary outcome for the meta-analysis. All statistical analyses were performed on the logit-transformed prevalence (i.e. the logarithm of the prevalence divided by its complement) estimated within each study. Variance and its standard error (SE) were estimated applying the Delta-method on the normal approximation of the distribution of such transformed estimate \[[@CR18]\]. The lower and upper bounds of each corresponding 95% confidence interval (95% CI) were calculated as the logit-transformed prevalence ±1.96 times SE and the 95% CI was further reported in its original scale by back transformation. As a subgroup analysis, the meta-analysis was stratified by study quality.

Between-study heterogeneity of epidemiological estimates was assessed using the Cochran's Q-test \[[@CR19]\] along with its derived measure of inconsistency (I^2^), and was considered to be present when Cochran's Q-test *p*-value was \< 0.10 or I^2^ \> 40% \[[@CR20]\]. Due to their dependence on the precision of included trials \[[@CR21]\], I^2^ was also corroborated by its 95%CI calculated following the Q-profile method \[[@CR22]\]. Study-specific outcomes were summarized by fixed-effects or random-effects logistic models, according to the absence or the presence of heterogeneity, respectively. In the latter case, meta-regression analyses were further performed to identify potential sources of heterogeneity (i.e. examining the contribution of different study-level covariates to the overall heterogeneity) and subgroups meta-analysis were also performed if necessary. The following variables were identified as potential sources of heterogeneity for further investigation: study design, the year in which the study started, study duration and the continent where the study was conducted. Examination of sources of heterogeneity was based on the statistical significance (from omnibus Wald-type test) evaluated to the examined variables. Moreover, the proportion of the between-studies variance which was explained by each study-level covariate was computed in terms of R^2^, which is defined as the ratio of the total between-studies variance explained by the study-level covariate to total between-studies variance computed from the random effects MA without the study-level covariate.

To investigate the presence of publication bias (which consists in the selective publication of studies in relation to their findings), a funnel plot showing the individual observed study outcome (on the x-axis) against the corresponding standard error (on the y-axis) was reported for each outcome at issue and the asymmetry of each funnel plot was evaluated by the rank correlation test, as proposed by Begg and Mazumdar \[[@CR23]\]. It is generally accepted that when there are fewer than ten studies in a meta-analysis, both meta-regression \[[@CR20]\] and test for publication bias \[[@CR24]\] should not be considered.

Study-specific prevalence estimates (along with their 95% CI) as well as the overall summary prevalence estimate were graphically represented (in log scale) with a forest plot: for each study, ordered by the publication year, a square was plotted whose center projection corresponded to the study-specific estimate. A diamond was used to plot the overall prevalence, the center of which represents the point estimate whereas the extremes of the summary estimate show the 95% CI.

Two-sided *p*-values\< 0.05 were considered for statistical significance. Statistical analyses were performed using SAS Software, Release 9.4 (SAS Institute, Cary, NC, USA) and R Foundation for Statistical Computing (version 3.6, package: metafor).

Results {#Sec6}
=======

Study selection and characteristics {#Sec7}
-----------------------------------

The flow-chart for study selection is shown in Fig. [1](#Fig1){ref-type="fig"}. Overall, the initial literature search identified 1951 studies. Following removal of duplicates (*N* = 520), 1431 abstracts were initially screened and only 57 (4.0%) full-text articles to review were retained for further evaluation. Of these, based on literature review, 44 (77.2%) studies containing information on the global epidemiology of DMD met the eligibility criteria and were therefore included in this systematic review. The detailed characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. Twenty-two studies (50%) reporting DMD prevalence \[[@CR25]--[@CR46]\] and 29 studies (65.9%) reporting DMD birth prevalence \[[@CR25]--[@CR27], [@CR30], [@CR34], [@CR37], [@CR39], [@CR47]--[@CR68]\] were included. Six studies (13.6%) reported both DMD prevalence and birth prevalence \[[@CR25], [@CR26], [@CR30], [@CR34], [@CR37], [@CR39]\]. The majority of the studies included (*N* = 28; 63.6%) were conducted in Europe. The geographical distribution of the studies included in the review is shown in Fig. [2](#Fig2){ref-type="fig"}. The studies conducted by Lefter et al., Norman et al., Leth et al. and Radhakrishnan et al. \[[@CR27], [@CR28], [@CR46], [@CR60]\] were excluded from the meta-analysis because the denominator used to calculate the prevalence was not reported in the full-text article. Fig. 1PRISMA flow-chart showing the process of literature search and study selectionTable 1Characteristics of the included studies on Duchenne muscular dystrophy epidemiologyAuthor, Year of publicationCatchment areaData sourcePopulationStudy yearsStudy designDMD definitionPrevalence typeEpidemiological estimate per 100,000\
\[95% CI\]DMD Prevalence Danieli, 1977 \[[@CR25]\]Four districts of Veneto Region (Italy)Hospital records reviewPatients with a diagnosis of DMD from 1952 to 19721952--1972Retrospective chart-review studyHigh serum CK levels on samples of fresh serum from subjects at rest and 6 h after vigorous physical exercisePeriod prevalence per 1000,000 males and females of any age3.4 \[2.8--4.2\] per 100,000 Monckton, 1982 \[[@CR26]\]Alberta (Canada)Hospital/clinic chart reviewCases recorded by three muscular dystrophy association Clinics as well as cases recorded at the Genetics Clinics of the University of Alberta and the Alberta Children's Hospital1950--1979Retrospective chart-review study--Point prevalence in 1979 per 100,000 males of any age9.5 \[7.8--11.6\] per 100,000 Leth, 1985 \[[@CR27]\]DenmarkCollection of data from hospital departments, nursery homes and general practitioners445 patients with progressive muscular dystrophy alive January 1st 19651965--1975Retrospective population-based cohort studyHistological changes in muscular tissue, typical electromyographic changes, high serum CK levels, family occurrence of progressive muscular dystrophyPoint prevalence per 1000,000 in 19656.94 per 100,000^a^ Radhakrishnan, 1987 \[[@CR28]\]Benghazi, LybiaHospital records reviewPatients resident of Benghazi with neuromuscular disorders over the period January 1983--19851983--1985Retrospective chart-review studyDMD diagnosis based on clinical examination, family history, serum CPK, electromyography and investigations to exclude acquired disordersPoint prevalence in 1985 per 100,0006.0 per 100,000^a^ Nakagawa, 1991 \[[@CR29]\]Okinawa (Japan)Hospital chart review (data collected from hospital departments, nursing homes and social health centers)Patients with DMD in the whole Okinawa prefecture1989Retrospective population-based cohort studyClinical presentation, high serum CK levels, electromyography, lens examination and immunohistochemical studies with antidystrophin antibodyPoint prevalence per 100,000 males of any age7.1 \[5.16--9.6\] per 100,000 males van Essen, 1992 \[[@CR30]\]The NetherlandsLinkage database containing Dutch DMD registry, National Medical Registration file, Death Registry, Medical Genetics databaseAll living DMD patients on January 1, 1983 in the Netherlands1961--1982Retrospective population-based cohort studyA score was given considering the clinical status, serum CK levels, electromyograms, muscle biopsy findings, electrocardiograms, and familial occurrence compatible with X-linked recessive inheritance, together with the CK levels in the mother and/or sister when availablePoint prevalence in 1983 per 100,000 males of any age5.4 \[4.9--6.0\] per 100,000 males Ahlström, 1993 \[[@CR31]\]Örebro (Sweden)Clinical chart and administrative data (e.g. early retirement pension, temporary disability pension) reviewPatients with a diagnosis of DMD between 1974 and 19871974--1988Retrospective chart-review study--Point prevalence in 1988 per 100,000 males and females of any age0.7 \[0.2--2.7\] per 100,000 Ballo, 1994 \[[@CR32]\]South AfricaReferrals requested from practitioners and genetic clinicsPatients with a diagnosis of DMD between 1987 and 19921987--1992Observational cohort study using retrospectively dataHigh serum CK levels, electromyography and genetic testingPeriod prevalence per 1000 males of any age0.9 \[0.8--1.1\] per 100,000 males Hughes, 1996 \[[@CR33]\]Northern IrelandPrimary data: Mailed surveySecondary data: hospital/clinic chart review, administrative data, patient registryPatients with DMD identified from the records of the North Ireland Muscle Clinic, the North Ireland Medical Genetic Department and from general practitioners, physicians and pediatricians data1993--1994Epidemiological survey. Population-based cohort study using prospectively and retrospectively collected dataNot specifiedPoint prevalence in 1994 per 1000,000 males and females of any age8.2 \[6.3--10.4\] per 100,000 Hughes, 1996 \[[@CR33]\]Northern IrelandPrimary data: mailed surveySecondary data: hospital/clinic chart review, administrative data, patient registryPatients with DMD identified from the records of the North Ireland Muscle Clinic, the North Ireland Medical Genetic Department and from general practitioners, physicians and pediatricians data1993--1994Epidemiological survey.Population-based cohort study using prospectively and retrospectively collected dataNot specifiedPoint prevalence in 1994 per 1000,000 males of any age4.3 \[3.3--5.4\] per 100,000 males Peterlin, 1997 \[[@CR34]\]SloveniaRegistries and medical records reviewDMD cases diagnosed in the period 1969--19841969--1984Retrospective population-based cohort studyDMD diagnosis based on the clinical picture, serum enzymes, electromyography and muscle biopsyPoint prevalence in 1990 per 100,000 males of any age2.9 \[2.0--4.2\] per 100,000 males Siciliano, 1999 \[[@CR35]\]North-West Tuscany (Italy)Primary data: mailed surveySecondary data: hospital/clinical records review, administrative databasesPatients treated in the Unit for Muscle Diseases, University of Pisa1997Epidemiological survey.Population-based cohort study using prospectively and retrospectively collected dataGenetic testing (genomic DNA analysis and dystrophin analysis), clinical exam, high serum CK levels, family history, muscle biopsyPoint prevalence per 100,000 males and females of any age1.7 \[1.1--2.6\] per 100,000 Darin, 2000 \[[@CR36]\]Western SwedenResidential and outpatient registers, muscle biopsy registries and administrative databasesAll individuals with neuromuscular disorders born between 1979 and 1994 and admitted in one of the seven hospitals in the region before 1st January 19951995Retrospective population-based cohort studyClinical exams, high serum CK levels, family history, muscle biopsy, genetic testingPoint prevalence per 100,000 males, aged less than 16 years16.8 \[11.4--23.8\] per 100,000 males Jeppesen, 2003 \[[@CR37]\]Aarhus (Denmark)Medical records of all DMD patients in the Institute of Neuromuscular Diseases, Respiratory Centre East at the State University Hospital and Respiratory Centre West at Aarhus University HospitalMale Danish population in the period January 1, 1977 to January 1, 2002 and Danish newborn males1977--2002Retrospective population-based cohort studyUntil 1993, ICD-8 code 330.39 (*dystrophia musculorum progressiva*) or subcode 330.38 (*dystrophia musculorum progressiva, typus Duchenne*); from 1994 onward, ICD-10 code G71.0 (*dystrophia musculorum*) or subcode G71.0H (*dystrophia musculorum gravis, Duchenne*)Point prevalence in 2002 per 100,000 males of any age5.5 \[4.6--6.5\] per 100,000 males Chung, 2003 \[[@CR38]\]Hong KongHospital/clinic chart review from two University teaching hospitals332 childrenaged \< 19 years at first assessment with neuromuscular diseases confirmed by using electromyography, muscle biopsy, and/or molecular genetic study1985--2001Prospective population-based cohort studyHigh serum CK level, nerve conduction study, electromyography, muscle biopsy, and molecular genetic study of blood DNAPoint prevalence in 2001 per 1000,000 males aged less than 19 years9.8 \[7.7--12.6\] per 100,000 males Talkop, 2003 \[[@CR39]\]EstoniaHospital/clinic chart review, mailed survey, administrative database, patient registryAll patients with DMD born and diagnosed in the period 1977--1999 in Estonia1994--1999Epidemiological survey.Observational cohort study using retrospectively collected dataNot specifiedPoint prevalence in 1998 per 100,000 males aged less than 20 years12.8 \[8.3--18.8\] per 100,000 males El-Tallawy, 2005 \[[@CR40]\]Assiut (Egypt)Door-to-door community survey52,203 subjects, identified from a door-to-door survey1996--1997Cross-sectional studyElectrophysiological and biochemical (high serum CK levels) investigations, genetic testing, muscle biopsyPoint prevalence in 1997 per 100,000 males and females of any age7.7 \[2.1--19.6\] per 100,000 Norwood, 2009 \[[@CR41]\]Northern EnglandDatabase of the Institute of Human Genetics in Newcastle and disease-specific databasesAll registered patients (children and adults) with inherited muscle diseases diagnosed and currently seen by the neuromuscular team at the Institute of Human Genetics at Newcastle University2007Retrospective population-based cohort studyGenetic testing and genetic investigations (deletion, duplication or point mutation in the DMD gene)Point prevalence per 100,000 males of any age8.3 \[6.8--9.8\] per 100,000 males Mah, 2011 \[[@CR42]\]CanadaDe-identified data consisting of the clinical phenotypes, diagnostic methods, and molecular genetic reports from DBMD patients from the Canadian Pediatric Neuromuscular GroupDBMD patients followed by participating Canadian Pediatric Neuromuscular Group centers2000--2009Retrospective population-based cohort studyClinical phenotypes, diagnostic methods (MLPA, muscular biopsy) and molecular genetic reportsPeriod prevalence per 10,000 males from birth to 24 years10.6 \[9.7--11.5\] per 100,000 males Rasmussen, 2012 \[[@CR43]\]South-Eastern NorwayProspectively collected patient dataPatients aged under 18 years treated by neuropediatricians2005Prospective population-based cohort studyGenetic testing (sequencing of the dystrophin gene) and/or muscular biopsyPoint prevalence per 100,000 males from birth to 18 years16.2 \[11.5--22.8\] per 100,000 males Romitti, 2015 \[[@CR44]\]USAMD STAR*net* databasePatients born from January 1982, to December 2011, resided in an MD STARnet site during any part of that time period, and was diagnosed with childhood-onset DBMD1982--2011Cross-sectional studyICD-9 CM code: 359.1 or ICD-10 CM code: G71.0Point prevalence in 2010 per 10,000 males aged 5--24 years10.2 \[9.2--11.2\] per 100,000 males Ramos, 2016 \[[@CR45]\]Puerto RicoData from 141 patients attending the Muscular Dystrophy Association neuromuscular clinics in Puerto Rico (4 clinics in total)141 patients attending the Muscular Dystrophy Association neuromuscular clinics in Puerto Rico2012Retrospective epidemiological survey"Definite" cases have symptoms referable to DMD and either (1) a documented DMD gene mutation, (2) muscle biopsy evidencing abnormal dystrophin without an alternative explanation, or (3) CK level at least 10 times normal, pedigree compatible with X-linked recessive inheritance, and an affected family memberPoint prevalence per 100,000 males of any age5.2 \[4.2--6.4\] per 100,000 males Lefter, 2016 \[[@CR46]\]Republic of IrelandDemographic, clinical, physiologic, histopathology, serology, and genetic data from retrospectively and prospectively identified patientsAdults (≥18 years old) living in the Republic of Ireland ≥5 years2012--2013Population-based study using retrospectively and prospectively collected dataGenetic and electrophysiological testsPoint prevalence in 2013 per 100,000 males (≥18 years old)3.0 \[2.3--3.7\] per 100,000 malesDMD Birth prevalence Brooks, 1977 \[[@CR47]\]South Eastern ScotlandSurvey and clinical records reviewAll cases of DMD who had been born between 1953 and 19681953--1968Retrospective epidemiological survey--Period birth prevalence26.5 \[19.9--35.2\] per 100,000 live male births Danieli, 1977 \[[@CR25]\]Four districts of Veneto Region (Italy)Hospital records reviewPatients with a diagnosis of DMD from 1952 to 19721952--1972Retrospective chart-review studyHigh serum CK levels on samples of fresh serum from subjects at rest and 6 h after vigorous physical exercisePeriod birth prevalence28.2 \[22.1--35.8\] per 100,000 live male births Takeshita, 1977 \[[@CR48]\]Shimane (Japan)Questionnaires sent to nurse-teachers in infant schools, primary schools and junior high schools in Shimane--1956--1970Epidemiological surveyNeurological exams, electromyography, high CPK levels, muscle biopsyPeriod birth prevalence20.8 \[13.3--32.6\] per 100,000 live male births Drummond, 1979 \[[@CR49]\]New ZealandProspectively collected patient data101 consecutive live births at St Helen's Hospital, Auckland, New Zealand--Cross-sectional studyHigh CPK levels in newborn blood spotBirth prevalence20.0 \[5.5--72.9\] per 100,000 live male births Cowan, 1980 \[[@CR50]\]AustraliaSurvey and clinical records reviewDMD cases in New South Wales and in the Australian Capital Territory between 160 and 19711960--1971Retrospective epidemiological survey--Period birth prevalence18.6 \[15.3--22.6\] per 100,000 live male births Danieli, 1980 \[[@CR51]\]Veneto Region (Italy)Hospital records reviewDMD cases born in the period 1959--19681952--1972Retrospective epidemiological surveyAbnormal CK valuesPeriod birth prevalence28.2 \[23.3--34.2\] per 100,000 live male births Bertolotto, 1981 \[[@CR52]\]Turin (Italy)Clinical records reviewAll DMD cases born in Turin between 1955 and 1974.1955--1974Retrospective epidemiological surveyHigh CPK levels and electromyographyPeriod birth prevalence24.2 \[19.3--30.5\] per 100,000 live male births Monckton, 1982 \[[@CR26]\]Alberta (Canada)Hospital/clinic chart reviewCases recorded by three muscular dystrophy associationClinics as well as cases recorded at the Genetics Clinics of the University of Alberta and the Alberta Children's Hospital1950--1979Retrospective chart-review study--Period birth prevalence26.2 \[21.7--31.5\] per 100,000 live male births Nigro, 1983 \[[@CR53]\]Campania Region (Italy)Prospectively collected patient dataDMD cases born in Campania from 1960 until 19711969--1980Cross-sectional studyDMD diagnosis based on age of onset of symptoms, age of onset of the chairbound stage, pseudohypertrophy of calf muscle, marked elevation of CPK levels, muscle biopsyPeriod birth prevalence21.7 \[18.5--25.3\] per 100,000 live male births Dellamonica, 1983 \[[@CR54]\]FranceProspectively collected patient dataBlood samples of 158,000 newborns obtained 4 to 8 days postnatally1978Cross-sectional studyHigh CPK levels in newborn blood spotBirth prevalence16.9 \[9.7--29.5\] per 100,000 live male births Leth, 1985 \[[@CR27]\]DenmarkCollection of data from hospital departments, nursery homes and general practitioners445 patients with progressive muscular dystrophy alive January 1st 19651965--1975Retrospective population-based cohort studyHistological changes in muscular tissue, typical electromyografic changes, high serum CK levels, family occurrence of progressive muscular dystrophyPeriod birth prevalence22.2 per 100,000^a^ Scheuerbrandt, 1986 \[[@CR55]\]West GermanyProspectively collected patient data--1977--1984Cross-sectional studyHigh CK activity in newborn blood spotPeriod birth prevalence27.2 \[20.5--36.0\] per 100,000 live male births Mostacciuolo, 1987 \[[@CR56]\]Five districts of Veneto Region (Italy)Hospital records reviewDMD cases born in the period 1959--19681955--1984Retrospective epidemiological surveyDMD diagnosis based on electromyography, muscle biopsy, serum enzymes, and clinical history of the patientsPeriod birth prevalence26.0 \[34.4--53.9\] per 100,000 live male births Takeshita, 1987 \[[@CR57]\]Western JapanData collected from the preschool development screening program, from public institutions for children and 5 hospitalsDMD cases born between 1956 and 19801956--1980Retrospective population-based cohort studyDMD diagnosis based on electromyography, serum CK levels and muscle biopsyPeriod birth prevalence19.1 \[14.5--25.2\] per 100,000 live male births Greenberg, 1988 \[[@CR58]\]CanadaProspectively collected patient data18,000 newborn males screened for DMD in the routine Manitoba perinatal screening program1986--1987Cross-sectional studyHigh CK levels in newborn blood spot, muscle biopsyPeriod birth prevalence27.8 \[11.9--65.0\] per 100,000 live male births Tangsrud, 1989 \[[@CR59]\]Southern NorwayClinical records and national databases reviewAll boys with a known history of Duchenne muscle dystrophy born during the period 1968--19771968--1977Retrospective chart-review studyMuscle biopsies, electromyographic changes, high serum CK levelsPeriod birth prevalence21.9 \[13.5--35.6\] per 100,000 males Norman, 1989 \[[@CR60]\]WalesRetrospectively and prospectively collected patient data--1971--1986Cross-sectional studyHigh CK levelsPeriod birth prevalence24.7 per 100,000 males^a^ van Essen, 1992 \[[@CR30]\]The NetherlandsLinkage database containing Dutch DMD registry, National Medical Registration file, Death Registry, Medical Genetics databaseAll males withDMD both born and diagnosed in the period 1961--1982 in the Netherlands1961--1982Retrospective population-based cohort studyA score was given considering the clinical status, serum CK levels, electromyograms, muscle biopsy findings, electrocardiograms, and familial occurrence compatible with X-linked recessive inheritance, together with the CK levels in the mother and/or sister when available.Period birth prevalence23.7 \[20.7--26.7\] per 100,000 live male births Merlini, 1992 \[[@CR61]\]Bologna (Italy)Clinical records reviewChildren born between 1970 and 1989 in Bologna (Italy)1970--1982Retrospective epidemiological survey--Period birth prevalence25.8 \[16.7--39.8\] per 100,000 live male births Bradley, 1993 \[[@CR62]\]WalesBlood samples obtained through screening program forphenylketonuria and congenital hypothyroidism in all maternity units throughout Wales--1990--1992Cross-sectional studyHigh CK levels in newborn blood spot, genetic testing, molecular genetic mutation analysis, muscle biopsy and dystrophin analysis.Period birth prevalence26.3 \[13.8--49.9\] per 100,000 live male births Peterlin, 1997 \[[@CR34]\]SloveniaRegistries and medical records reviewDMD cases diagnosed in the period 1969--19841969--1984Retrospective population-based cohort studyDMD diagnosis based on the clinical picture, serum enzymes, electromyography and muscle biopsyPeriod birth prevalence13.8 \[9.6--19.8\] per 100,000 live male births Drousiotou, 1998 \[[@CR63]\]Cyprus5170 blood samples obtained through the national screening center for phenylketonuria and congenital hypothyroidism30,014 newborn males screened for DMD1992--1997Cross-sectional studyHigh CK levels in newborn blood spotPeriod birth prevalence16.7 \[7.1--39.0\] per 100,000 live male births Jeppesen, 2003 \[[@CR37]\]Aarhus (Denmark)Medical records of all DMD patients in the Institute of Neuromuscular Diseases, Respiratory Centre East at the State University Hospital and Respiratory Centre West at Aarhus University HospitalDanishlive born males from 1972 to 20011992--1996Retrospective population-based cohort studyUntil 1993, ICD-8 code 330.39 (dystrophia musculorum progressiva) or subcode 330.38 (dystrophia musculorum progressiva, typus Duchenne); from 1994 onward, ICD-10 code G71.0 (dystrophia musculorum) or subcode G71.0H (dystrophia musculorum gravis, Duchenne)Period birth prevalence18.8 \[12.4--25.2\] per 100,000 live male births Talkop, 2003 \[[@CR39]\]EstoniaHospital/clinic chart review, mailed survey, administrative database, patient registryAll patients with DMD born and diagnosed in the period 1977--1999 in Estonia1986--1990Observational cohort study using retrospectively collected dataNot specifiedPeriod birth prevalence17.7 \[8.8--31.6\] per 100,000 live male births Eyskens, 2006 \[[@CR64]\]Antwerp (Belgium)Prospectively collected patient data281,214 newborn males screened for dystrophinopathy1979--2003Cross-sectional studyHigh CK levels in newborn blood spotPeriod birth prevalence18.2 \[7.1--39.0\] per 100,000 live male births Dooley, 2010 \[[@CR65]\]Nova Scotia (Canada)Records of DMD diagnosis from the Pediatric Neurology Division (Dalhousie University) and the IWK Health CentreAll patients with DMD in Nova Scotia1969--2003Retrospective population-based cohort studyMuscle biopsy or genetic testingPeriod birth prevalence21.3 \[13.8--23.8\] per 100,000 live male births Mendell, 2012 \[[@CR66]\]Ohio (USA)Prospectively collected patient data37,649 newborn male subjects screened for DMD2007--2011Cross-sectional studyHigh CK levels in newborn blood spot and genetic testing (MLPA)Period birth prevalence15.9 \[7.3--34.8\] per 100,000 live male births Moat, 2013 \[[@CR67]\]WalesBlood spots collected routinely as part of the Wales newborn screening program343,170 newborn blood spots screened for DMD1990--2011Cross-sectional studyHigh CK levels in newborn blood spotPeriod birth prevalence19.5 \[15.4--24.5\] per 100,000 live male births König, 2019 \[[@CR68]\]GermanyNeuromuscular centers, genetic institutes and the German patient registriesPatients with either dystrophinopathies or SMA born between 1995 and 2018.1995--2018Retrospective epidemiological study--Point birth prevalence1.5 \[0.7--3.3\] per 100,000 live male births*Abbreviations*: *CK* Creatinine kinase, *DBMD* Duchenne/Becker muscular dystrophy, *DMD* Duchenne muscular dystrophy, *ICD-8* International Statistical Classification of Diseases and Related Health Problems, 8th edition, *ICD-9* International Statistical Classification of Diseases and Related Health Problems, 9th edition, *ICD-10* International Statistical Classification of Diseases and Related Health Problems, 9th edition, *MPLA* Multiplex ligation-dependent probe amplification^a^95% confidence intervals could not be calculated as the crude numbers required to calculate the epidemiological estimate were not provided in the papersFig. 2Geographical distribution of the Duchenne muscular dystrophy epidemiological studies included in the systematic review

Quality of study reporting assessment {#Sec8}
-------------------------------------

Overall, the quality of 44 studies was evaluated. In total 36 (81.8%) studies were assessed as being of medium and 8 (18.2%) being of low quality, while no study was assessed as having a high overall quality. Study design and setting were adequately reported in the majority of the studies included in this review (84.1%), while participants were adequately characterized only in 9.1% of the studies. On the contrary, the description of DMD identification was appropriate in 84.1% and unclear in 11.4% of the articles included. Figure [3](#Fig3){ref-type="fig"} summarizes the overall quality of study reporting, which was estimated for all the 44 studies included. More detail about the quality of each included study is reported in Additional file [4](#MOESM4){ref-type="media"}. Fig. 3Quality of Duchenne muscular dystrophy epidemiological studies reporting assessment

Pooled DMD overall and birth prevalence {#Sec9}
---------------------------------------

Of the 22 studies reporting DMD prevalence, 13 (59.1%) were European \[[@CR25], [@CR27], [@CR30], [@CR31], [@CR33]--[@CR37], [@CR39], [@CR41], [@CR43], [@CR46]\], 4 (18.2%) American \[[@CR26], [@CR42], [@CR44], [@CR45]\], 2 (9.1%) Asian \[[@CR29], [@CR38]\] and 3 (13.6%) were African \[[@CR32], [@CR40]\].

The majority of the studies evaluated DMD prevalence through secondary use of data such as clinical charts, administrative databases and patient or disease registries, apart from the study conducted by El-Tallawy et al. \[[@CR40]\], which was based on a community survey. The global prevalence of DMD ranged from 0.9 \[[@CR32]\] to 16.8 \[[@CR36]\] cases per 100,000 males, including a population of neonates to the oldest surviving adults. When considering the general population (i.e. males and females), the global prevalence of DMD ranged from 0.7 to 7.7 cases per 100,000, with the lowest value in Sweden \[[@CR31]\] and the highest value in Egypt \[[@CR40]\]. The pooled DMD prevalence was 7.1 cases (95% CI: 5.0--10.1) per 100,000 males and 2.8 cases (95% CI: 1.6--4.6) per 100,000 persons (i.e. males and females together) (Fig. [4](#Fig4){ref-type="fig"}). A substantial heterogeneity was detected both in males (Cochran's Q = 856.45, I^2^ = 98.5%, *p* \< 0.001) and in the whole population (Cochran's Q = 21.29, I^2^ = 87.4%, *p* \< 0.001). The 95% CI for such I^2^ statistics were 97.2--99.4% and 63.0--99.4%, respectively. However, it is difficult to interpret these findings as heterogeneous on the basis of 5 studies only. Fig. 4Forest plot of the estimated Duchenne Muscular Dystrophy prevalence per 100,000 cases along with 95% confidence interval in studies which included (in the total population), among male individuals only and the ones which included male and female individuals, separately

Of the 29 studies reporting DMD birth prevalence, 21 (72.4%) were European \[[@CR25], [@CR27], [@CR30], [@CR34], [@CR37], [@CR39], [@CR47], [@CR51]--[@CR56], [@CR59]--[@CR64], [@CR67], [@CR68]\], 4 (13.8%) were American \[[@CR26], [@CR58], [@CR65], [@CR66]\], 2 (6.9%) were Oceanian \[[@CR49], [@CR50]\] and 2 (6.9%) were Asian \[[@CR48], [@CR57]\] studies. The global birth prevalence of DMD range was very wide: from 1.5 to 28.2 cases per 100,000 live male births in Germany and Italy, respectively \[[@CR25], [@CR51], [@CR68]\]. Eighteen studies (62.1%) \[[@CR25]--[@CR27], [@CR30], [@CR34], [@CR37], [@CR39], [@CR47], [@CR48], [@CR50]--[@CR52], [@CR56], [@CR57], [@CR59], [@CR61], [@CR65], [@CR68]\] were conducted using secondary data and 11 (37.9%) \[[@CR49], [@CR53]--[@CR55], [@CR58], [@CR60], [@CR62]--[@CR64], [@CR66], [@CR67]\] using primary data collection, based on questionnaires, blood samples analysis, muscle biopsy and genetic screening. The pooled global birth prevalence was 19.8 cases (95% CI:16.6--23.6) per 100,000 live male births (Fig. [5](#Fig5){ref-type="fig"}). A substantial heterogeneity was seen among these studies (Cochrane's Q = 82.03, I^2^ = 89.8%, *p* \< 0.001) with a 95%CI for I^2^ ranging from 75.5 to 95.8%. Fig. 5Forest plot of the estimated Duchenne Muscular Dystrophy birth prevalence per 100,000 cases, along with 95% confidence interval

The stratification was only possible for medium quality studies (*N* = 36), because there were too few studies of low quality (*N* = 4) and no studies of high quality. The pooled estimate from random effects meta-analysis including all studies with medium quality was 6.8 (4.5--10.2) (I^2^ = 98.4%) and 19.5 (16.3--23.5) (I^2^ = 90.6%) concerning DMD prevalence and birth prevalence, respectively.

A visual inspection of the data suggested several outliers, namely Ballo et al. and Peterlin et al. who had very low values for prevalence per 100,000 males while and Darin et al. and Rasmussen et al. had very high values for this same outcome. However, no qualitative differences in study methodology to justify their impact on the pooled estimates were observed. Concerning birth prevalence, König et al. were found to be outliers. This study had problems with data collection in the last study year, as due to privacy issues, DMD cases were under-reported. No publication bias was found based on the funnel plot and Begg and Mazumdar's rank correlation test for asymmetry both for DMD prevalence and birth prevalence (*p*-values = 0.771 and 0.184, respectively) (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6Funnel plots for the estimated Duchenne Muscular Dystrophy (DMD) prevalence in males (panel **a**) and DMD birth prevalence (panel **b**) along with Begg and Mazumdar's rank correlation test for asymmetry

Exploration of sources of heterogeneity {#Sec10}
---------------------------------------

In order to explore the sources of heterogeneity of worldwide prevalence estimates, a meta-regression analysis was performed for DMD (males only) and birth DMD outcomes, separately. Meta-regression analysis was not performed in DMD general population because less than 10 studies were available. Since the point prevalence was estimated for almost all DMD studies whereas the period prevalence for almost all birth DMD studies, the information about prevalence type was not considered into the meta-regression analysis.

None of the study level covariates significantly reduced the between-study heterogeneity estimated from the random-effects meta-analysis (i.e. the proportion of explained heterogeneity R^2^ was always lower than 20%) with exception of the "study period" which significantly explained such heterogeneity between DMD birth prevalence study estimates (Wald-type test *p* \< 0.001, *R*^2^ = 45%) although a high residual heterogeneity still remained (I^2^ = 83.1, 95%CI = 64.2--94.9%) (Table [2](#Tab2){ref-type="table"}). Table 2Results of meta-regression analysis Duchenne Muscular Dystrophy (DMD) prevalence and birth prevalenceOutcomeSubgroupStudy-level covariate(s) included into the meta-regressionHeterogeneity assessmentCovariate(s) selected***p***-value\*Cochran's Q (df)***p***-value (Q test)I^**2**^ (%)Between-study variance^**e**^***R***^**2**^ (%)^f^DMD prevalenceMales only (15 studies)None (random-effects MA)--856.4531 (df = 14)\< 0.000198.46%0.4741--Continent^a^0.2027450.7452 (df = 12)\< 0.000197.90%0.385718.65%Study year (begin) + Study duration0.4195632.8951 (df = 12)\< 0.000197.89%0.422710.84%Study design^c^0.6429572.9228 (df = 12)\< 0.000198.40%0.44526.10%DMD birth prevalenceAll (27 studies)None (random-effects MA)--82.0309 (df = 26)\< 0.000189.79%0.1646--Continent^b^0.930874.7046 (df = 23)\< 0.000188.90%0.16191.64%Study year (begin) + Study duration0.001260.8329 (df = 23)\< 0.000183.13%0.090545.02%Study design^d^0.318978.8714 (df = 24)\< 0.000187.51%0.14839.90%*MA* Meta-analysis, *I*^*2*^ Measure of inconsistency, *df* Degrees of freedom referred to the Cochran's Q test\**P*-values from omnibus Wald-type test of parameters (i.e. study-level covariates included into the model)^a^Continents were regrouped as follows: America North (US and Canada) (4 studies), Europe North/Centre/East (8 studies), Others (Asia East and Africa South) (3 studies)^b^Continents were regrouped as follows: America North (US and Canada) (4 studies), Asia East and Australia/New-Zealand (4 studies), Europe Centre/East/South (13 studies), Europe North (6 studies)^c^Study designs were regrouped as follows: Observational cohort (3 studies), Retrospective cohort/chart-review/cross-sectional (9 studies), epidemiological survey (3 studies)^d^Study designs were regrouped as follows: Cross-sectional (10 studies), Prospective cohort and survey (8 studies), Retrospective cohort/chart-review (9 studies)^e^Total and residual between-study variance: the overall heterogeneity corresponds to the total between-study variance estimated from random-effects MA whereas the residual heterogeneity corresponds to between study-variance explained by the study-level covariates included into meta-regression model^f^R^2^ is the proportion of the overall heterogeneity (i.e. the total between-study variance) which is "explained" (i.e. reduced) by the effect of the included study-level covariate

Discussion {#Sec11}
==========

This systematic review provides an updated broad overview on the global epidemiology of DMD, including an evaluation of the quality of study reporting along with testing for publication bias. To our knowledge, this is the first comprehensive systematic review which evaluated the pooled global epidemiology of DMD. The pooled global prevalence and birth prevalence of DMD were 7.1 (95% CI: 5.0--10.1) and 19.8 (95% CI: 16.6--23.6) per 100,000 males, respectively. The birth prevalence is much higher than the prevalence because children with DMD may not survive beyond pediatric age likely in developing Countries with low adherence to standards of care. When considering as denominator the general population, the pooled global prevalence of DMD decreases, as expected, to 2.8 (95% CI: 1.6--4.6) cases per 100,000 as only males can be affected by the disease. Although epidemiological estimates were comparable in most studies, various outliers were found. The accuracy of these estimates could be strongly affected by different data sources (i.e. primary or secondary data), study design (e.g. prospective vs. retrospective studies, longitudinal vs. cross-sectional studies etc.), case definitions, inclusion criteria, sample sizes and DMD diagnostic methods, that could lead to extremely variable epidemiological estimations. In the present study we were not able to stratify results by ethnicity as this was not reported in all the studies; this might be important as it is known that some rare diseases such as Gaucher's disease are known to be more common in specific ethnic groups, such as Ashkenazi Jews \[[@CR69]\]. It was also not possible to compare the epidemiology across different countries, because of the small number of studies and large heterogeneity among the conducted studies.

Pooling the results of the different epidemiological studies, especially in the case of rare diseases, is particularly advantageous, since this increase of the total sample size allows more robust estimates and accounts for the potential differences among the included studies. Since the prevalence estimated within each included study was corroborated by a very small 95%CI (i.e. by a very small within-study variability or, in other words, by a very high precision) and since the I^2^ can be also expressed in terms of both the within-study variability (w) and the between-studies variability (b) components as follows: b/(w + b), it is clear that relatively small within-study variability will result in large I^2^ estimates (and this was the case) \[[@CR21]\]. In response to this shortcoming, I^2^ estimates were also accompanied by their associated 95% CI \[[@CR70], [@CR71]\] because imprecise or biased estimates of heterogeneity can have serious consequences: for instance its overestimation may trigger inappropriate exploration of the cause(s) of heterogeneity. Nevertheless, such meta-analysis improves the accuracy and the reliability of the pooled estimate. The meta-regression analysis was useful to identify possible sources of heterogeneity by means of the use of study-level covariates. Interestingly, the only covariate which reduced the highest proportion of heterogeneity (about 45%) among DMD birth prevalence estimates was the year in which the study was carried out and its duration. The remaining heterogeneity could not be statistically accounted for.

Most studies included in this review were European, while only seven studies (15.9%) were identified from North America and no studies from South America were found. Overall, only 9 studies were found in Asia, Africa, Australia and New Zealand, all dated prior to 2005. Epidemiological research is essential to assess the population impact of rare diseases and to support public health decision-making: while epidemiological research can inform and improve public policy, public policy can also encourage and support epidemiological research. In Europe, rare diseases are among the priorities in public health research identified by the European Commission as of 2007 through FP7 programs and later through Horizon 2020 funding programs \[[@CR72]\]. It may not be a coincidence that a review on public policy conducted in 2018 suggested that the European countries presented the most unified approach to rare diseases, while no rare disease policies were found in Africa, India and Russia \[[@CR73]\].

The majority of the studies included used real-world data sources, such as claims databases, electronic medical records (EMRs) and patient/disease registries. Such data sources have a significant, and often under-used, potential to study rare diseases and to carry out accurate epidemiological evaluations \[[@CR74]\]. The main advantage of using real-world data sources is the size of the catchment population, which is often very large, in the order of millions \[[@CR75]\]. While this is an advantage in any research setting, it is particularly valuable to study rare diseases because the incidence of these diseases is so low.

However, there are also limitations to using each specific type of secondary data such as those from claims databases, EMRs and/or registries. One of the principal obstacles in using these data sources to study rare diseases is related to disease coding through systems such as International Classification of Diseases, 9th Revision (ICD-9), International Classification of Diseases, 10th Revision (ICD-10) and so on. While this is most relevant for claims and EHRs, some registries may also use ICD or similar codes \[[@CR74]\].

Rare diseases commonly do not have a medical code specific to them. Taking DMD as an example, the ICD-9 code refers to muscular dystrophy in general, which includes but is not limited to DMD (ICD9-CM code: 359.1) \[[@CR74]\]. Similarly, the ICD-10 code closest to DMD includes DMD but is not specific to it as it refers to Duchenne or Becker's muscular dystrophy (ICD-10 code: G71.01). As a result, the specificity of the diagnosis in data systems that use these codes is not very high in DMD and in rare diseases with similar issues. One solution to this problem might be linking claims databases/electronic medical records to registers of rare diseases from the same catchment area, whenever available, to validate DMD diagnoses recorded in claims databases by comparing them to the gold standard diagnosis, i.e. the diagnosis in patient registers \[[@CR74]\]. This approach was followed in the study conducted by König et al. \[[@CR68]\], where DMD patients where identified through the linkage of clinical records and patient registers. However, even this approach has its limitations: the DMD prevalence measured in the study conducted by König et al. fell significantly (from 11.7 per 100,000 in 2014 to 1.5 per 100,000 in 2017) in the last few years of the study due to missing data as a result of privacy issues.

The role of patient registers in the published literature has been acknowledged as an important real-world data source on rare diseases for many years, although they have been underused because of barriers to data access. Registers provide a unique opportunity to follow the natural history of the disease in time \[[@CR76]\]. The main limitation of registers with regards to the epidemiology of a rare disease is that the catchment area and its population (i.e. the denominator, whether in persons or person-years) may not be clearly defined. This would make it difficult to estimate the frequency of the diagnosis being made.

Apart from disease coding, another common tool for DMD identification in the studies included in the present review was genetic testing. Genetic testing for DMD is arguably the most reliable method of identifying DMD patients. There are at least three types of genetic tests available for DMD to date, i.e. tests for genetic duplications or deletions, CGH-array and direct sequencing. However, it is likely that quality of these tests increased over time. As a result, the reliability of DMD identification in earlier studies may not be as accurate as more recently conducted studies. In general, the identification of DMD patients in secondary data sources based on a diagnosis which is not directly associated with a genetic test is likely to be a less valid method than an identification method which is based primarily on genetic testing. However, the more accurate identification of true cases, for example, by genetic testing, does not necessarily lead to more accurate epidemiological estimates. Two studies which both used genetic testing to identify DMD reported much a higher prevalence per 100,000 males than the pooled estimate and were not consistent with other studies: Darin et al. \[[@CR36]\] who reported a prevalence of 16.8 (95% CI: 11.8--23.8) and Rasmussen et al. \[[@CR43]\], who reported a prevalence of 16.2 (95% CI: 11.4--22.9). The common elements between these two studies are the relatively low number of cases and the low number of persons in the source population, compared to other studies reporting the prevalence. These studies are more prone to over- or under-estimate the true number of cases based on a small sample size, even though they used genetic testing to identify DMD. This could in turn contribute to heterogeneity.

The overall quality of the studies, which reflects the transparency of reporting, included in the present review was assessed using a checklist adapted from STROBE. The results of the assessment suggest that the overall quality of study reporting was medium to low. In particular, although the majority of the studies adequately described the study design and setting, most of them did not report the eligibility criteria or an adequate characterization of the study participants (e.g. mean age, ethnicity). In some cases, this was in line with the research question of the studies, which did not address DMD alone but with other dystrophies \[[@CR26]--[@CR29], [@CR32]--[@CR36], [@CR38], [@CR40]--[@CR46], [@CR53], [@CR56], [@CR59], [@CR61], [@CR68]\]. Future studies should address the clinical picture of DMD patients on a large scale, as this is very informative concerning several aspects such as unmet clinical needs, overall survival and cost of care. The quality of reporting and the transparency in how the research was carried out are important because they impact how useful the study is \[[@CR77]\]. This has been highlighted for observational research in epidemiology in general, but may be even more important for rare diseases, since the manner in which data is collected and the data analysis is carried out can potentially lead to a very large variability of results due to the very small sample size. An additional problem that follows is that it becomes very difficult to replicate studies. From the present paper, it is clear that the transparency of reporting of observational studies concerning DMD needs to improve significantly.

Strengths and limitations {#Sec12}
-------------------------

The main strengths of our systematic review and meta-analysis are the exhaustive literature search strategy and the double review process as well as the inclusion of studies published very recently. Meta-regression analysis is another strength of this study, which allowed us to identify the main drivers of heterogeneity. Moreover, we restricted the meta-analysis for medium quality studies, in order to have an estimate that is not affected by low-quality studies. Nevertheless, the stratified meta-analysis was in line with the main results.

However, several limitations should be considered. We have tried to describe the studies in as much detail as possible, including the heterogeneity among them. The quality of our analyses could be affected by the intrinsic limitations of each included article and the different DMD outcome definitions of the individual studies could compromise the internal validity of this meta-analysis. Furthermore, although no publication bias was found, the between-studies heterogeneity was very high. Moreover, we were not able to stratify our results by ethnicity as this was not reported in all the studies.

Conclusion {#Sec13}
==========

To our knowledge, this is the first systematic review to evaluate the pooled global epidemiology of DMD and to assess the quality of study reporting. Due to the wide differences between each study (e.g. study design and setting, study population, data sources, case ascertainment, etc.) DMD prevalence and birth prevalence estimates are variable throughout the literature, ranging 0.9 to 16.8 per 100,000 males from 1.5 to 28.2 per 100,000 live male births, respectively. The pooled prevalence and birth prevalence were 5.3 (95% CI: 5.1--5.5) cases per 100,000 males and 21.4 (95% CI: 20.4--22.5) cases per 100,000 live male births respectively. Generating epidemiological evidence on DMD is fundamental to support public health decision-making in allocating resources considering the high disease's costs related to the need of multidisciplinary care, the elevated direct and indirect burden of patients and caregivers and the recently available expensive therapies. The overall quality of epidemiological studies on DMD was relatively low, highlighting the need for high quality studies in this field. High quality studies with more transparent reporting are required to better understand the epidemiology of DMD.
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